---
title: "Craig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289926672.md"
description: "Craig-Hallum analyst Albert Lowe maintains a Buy rating on SAB Biotherapeutics (SABS) with a $6.00 price target. Lowe, a 4-star analyst in the Healthcare sector, has a 6.9% average return. This contrasts with the broader market consensus, which suggests a Strong Buy rating for SABS with an average price target of $11.75."
datetime: "2026-06-16T13:15:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289926672.md)
  - [en](https://longbridge.com/en/news/289926672.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289926672.md)
generator: "portal-rs"
---

# Craig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)

In a report released today, Albert Lowe from Craig-Hallum maintained a Buy rating on SAB Biotherapeutics, with a price target of $6.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

According to TipRanks, Lowe is a 4-star analyst with an average return of 6.9% and a 41.35% success rate. Lowe covers the Healthcare sector, focusing on stocks such as Cardiff Oncology, Neurogene, and Compass Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for SAB Biotherapeutics with a $11.75 average price target.

### Related Stocks

- [SABS.US](https://longbridge.com/en/quote/SABS.US.md)
- [CRDF.US](https://longbridge.com/en/quote/CRDF.US.md)
- [NGNE.US](https://longbridge.com/en/quote/NGNE.US.md)
- [CMPX.US](https://longbridge.com/en/quote/CMPX.US.md)
- [SABSW.US](https://longbridge.com/en/quote/SABSW.US.md)

## Related News & Research

- [Chardan Capital Keeps Their Buy Rating on SAB Biotherapeutics (SABS)](https://longbridge.com/en/news/286193633.md)
- [Trump Is Still Very Much Operating Off ‘Concepts’ Of A Health Care Plan](https://longbridge.com/en/news/298872418.md)
- [RBC Capital Keeps Their Hold Rating on Sanofi (SNYNF)](https://longbridge.com/en/news/298984745.md)
- [Stifel Nicolaus Keeps Their Hold Rating on Sionna Therapeutics, Inc. (SION)](https://longbridge.com/en/news/299037622.md)
- [Exelixis Rated Hold as Zanzalintinib CRC Outlook Remains Mixed; $54 Price Target Reaffirmed](https://longbridge.com/en/news/298937347.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**